Compare STDN & FTRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STDN | FTRE |
|---|---|---|
| Founded | 2024 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Medical Specialities |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.9B |
| IPO Year | 2026 | 2023 |
| Metric | STDN | FTRE |
|---|---|---|
| Price | $12.48 | $20.92 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 13 |
| Target Price | $17.56 | ★ $21.04 |
| AVG Volume (30 Days) | 439.1K | ★ 1.5M |
| Earning Date | 11-20-2026 | 10-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $2,723,400,000.00 |
| Revenue This Year | $439.23 | N/A |
| Revenue Next Year | $259.21 | $3.19 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1.00 |
| 52 Week Low | $7.05 | $8.55 |
| 52 Week High | $17.34 | $23.51 |
| Indicator | STDN | FTRE |
|---|---|---|
| Relative Strength Index (RSI) | 46.23 | 61.23 |
| Support Level | $11.46 | $15.77 |
| Resistance Level | $13.73 | $21.25 |
| Average True Range (ATR) | 0.95 | 1.03 |
| MACD | 0.00 | 0.05 |
| Stochastic Oscillator | 27.52 | 44.39 |
Standard Nuclear Inc is an independent advanced nuclear fuel company. The company designs, engineers, and manufactures advanced nuclear fuels, with a primary focus on TRISO fuel for advanced reactors. Its operations include industrial-scale TRISO fuel manufacturing and the development of fuel for advanced reactors that utilize TRISO fuel. The company operates in a single operating and reportable segment, as it is engaged in a single business activity of TRISO production. It derives revenue from fuel development and services agreements. Geographically, the maximum revenue is generated from the United States.
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion.